ICER releases draft evidence report on crisaborole and dupilumab for atopic dermatitis
The Institute for Clinical and Economic Review (ICER), a US non-profit organization, has released a Draft Evidence Report assessing the comparative clinical effectiveness of crisaborole for treatment of mild-to-moderate atopic dermatitis in adults and children, and the clinical effectiveness and value of and dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults.
Crisaborole, trade name Eucrisa, was developed by US pharma giant Pfizer (NYSE: PFE) and received US Food and Drug Administration approval in December 2016, while Dupixent (dupilumab), from French pharma major Sanofi (Euronext: SAN) and US biotech Regeneron (Nasdaq: REGN), is currently under regulatory review.
The report, as well as accompanying draft voting questions, is now open to public comment for four weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze